Charon Robbin Ganellin

Title: Charon Robbin Ganellin: Innovator in Histamine Receptor Research

Introduction

Charon Robbin Ganellin is a notable inventor based in Hertfordshire, GB. She has made significant contributions to the field of pharmacology, particularly in the development of compounds that interact with histamine receptors. Her work has implications for various therapeutic applications.

Latest Patents

Ganellin holds a patent for "Imidazole derivatives as histamine receptor H3 (ANT) agonists." This patent includes novel imidazole derivatives that serve as histamine receptor H antagonists and/or agonists. The patent outlines the preparation of these compounds and their therapeutic uses. It also describes chemical compounds designed for use as histamine receptor H agonists, partial agonists, or antagonists, characterized by general formulas (Ia) or (Ib). Furthermore, the patent details methods for revealing the agonist, partial agonist, or antagonist activity of such compounds in vivo.

Career Highlights

Throughout her career, Ganellin has focused on the development of innovative chemical compounds that can be utilized in drug formulation. Her research has contributed to a deeper understanding of histamine receptors and their role in various physiological processes.

Collaborations

Ganellin has collaborated with esteemed colleagues in her field, including Jean-Charles Schwartz and Jean-Michel Arrang. These partnerships have enhanced her research and expanded the impact of her work.

Conclusion

Charon Robbin Ganellin is a pioneering inventor whose research on histamine receptor interactions has led to valuable advancements in pharmacology. Her contributions continue to influence the development of new therapeutic agents.